Dr. Brugarolas is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
5323 Harry Hines Blvd
Dallas, TX 75390Phone+1 214-648-4059- Is this information wrong?
Summary
Clinical Expertise
- Kidney Neoplasms, Renal cell carcinoma, Urologic oncology, Hematologic oncology
Education & Training
- Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 2001 - 2003
- Duke University HospitalResidency, Internal Medicine, 1998 - 2001
- Massachusetts Institute of TechnologyPhD, Biology, 1993 - 1998
- Universidad de Navarra Faculty of MedicineClass of 1993
Certifications & Licensure
- TX State Medical License 2006 - 2024
- MA State Medical License 2002 - 2007
- NC State Medical License 1998 - 2004
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Principal Investigator, Kidney Cancer Specialized Program of Research Excellence (SPORE) National Cancer Institute
- Elected to the American Society for Clinical Investigation 2013
- Individual Investigator Research Award Cancer Prevention and Research Institute of Texas, 2010
- Join now to see all
Publications & Presentations
PubMed
- Phase 2 Trial of Stereotactic Ablative Radiotherapy for Patients with Primary Renal Cancer.Raquibul Hannan, Mark F McLaughlin, Laurentiu M Pop, Ivan Pedrosa, Payal Kapur, Aurelie Garant, Chul Ahn, Alana Christie, James Zhu, Tao Wang, Liliana Robles, Deniz Du...> ;European Urology. 2023 Mar 8
- 2 citationsIn vivo characterization of glutamine metabolism identifies therapeutic targets in clear cell renal cell carcinoma.Akash K Kaushik, Amy Tarangelo, Lindsey K Boroughs, Mukundan Ragavan, Yuanyuan Zhang, Cheng-Yang Wu, Xiangyi Li, Kristen Ahumada, Jui-Chung Chiang, Vanina T Tcheuyap, ...> ;Science Advances. 2022 Dec 16
- HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans.Yuanqing Ma, Allison Joyce, Olivia Brandenburg, Faeze Saatchi, Christina Stevens, Vanina Toffessi Tcheuyap, Alana Christie, Quyen N Do, Oluwatomilade Fatunde, Alyssa M...> ;Clinical Cancer Research. 2022 Dec 15
- Join now to see all
Press Mentions
- Stereotactic Radiation Highly Effective for Kidney CancerMay 2nd, 2017
- UT Southwestern Finds Determining Factor in Kidney Cancer AggressivenessAugust 14th, 2017
- Findings Establish PT2385 as a Highly Specific HIF-2 Inhibitor for Patients with Clear Cell RCCFebruary 27th, 2020
- Join now to see all
Grant Support
- Specialized Program of Research Excellence (SPORE)NIH/NCI2016–Present
Committees
- Chair, Scientific Advisory Board, National Kidney Cancer Academy 2020 - Present
- Chair, Congressionally Directed Medical Research Program – Kidney Cancer Research Program 2017 - 2018
Professional Memberships
- Member
- Member
- American Society for Clinical Investigation - ASCIMember
Other Languages
- Spanish
Hospital Affiliations
- University of Texas Southwestern Medical CenterDallas, Texas
External Links
- Kidney Cancer Programhttp://www.utsouthwestern.edu/kidneycancer
- Brugarolas Labhttp://www3.utsouthwestern.edu/brugarolaslab
- Kidney Cancer SPOREhttps://trp.cancer.gov/spores/kidney.htm
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: